63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT)

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a Prospectus Supplement No. 6 dated April 29, 2026. The supplement attaches a Form 8-K that discloses a Board and CEO succession and a consulting agreement with former director Dr. Eli Wallace.

The Form 8-K states Pedro J. Beltran, Ph.D. succeeded Dr. Wallace as President and Chief Executive Officer effective April 20, 2026, and the Company entered a consulting agreement effective April 21, 2026 for a twelve-month term that provides for continued vesting of Dr. Wallace’s outstanding equity awards and severance rights under the Company’s Executive Severance Plan.

Insights

Corporate Governance Analyst

Succession and consulting arrangements disclosed; selling holders registered shares.

The filing registers 63,054,549 shares for resale by selling securityholders, reflecting a resale registration and not an issuer primary sale. The Prospectus Supplement attaches a Form 8-K that documents a CEO transition effective April 20, 2026 and a consulting agreement effective April 21, 2026.

Key dependencies include the Consulting Agreement terms (to be filed as an exhibit) and the Executive Severance Plan adopted August 11, 2025. Cash‑flow treatment for the resale proceeds is not described in this excerpt; subsequent filings may specify plan exhibits and cash‑flow mechanics.

Securities & Capital Markets Counsel

Registration is a resale prospectus supplement; standard disclosure practice.

The Prospectus Supplement updates the S-1 registration by adding a selling securityholder resale amount and incorporates the Form 8-K by reference. The resale nature implies proceeds will flow to selling holders, consistent with the supplement's description of "Shares of Common Stock by the Selling Securityholders."

Material exhibits referenced (Consulting Agreement, Executive Severance Plan) are or will be filed; review of those exhibits is needed to assess any transfer restrictions, lockups, or exercise windows that could affect near-term share availability.

Key Figures

Registered shares: 63,054,549 shares Closing price: $8.80 per share Consulting term: 12 months +3 more

6 metrics

Registered shares 63,054,549 shares Prospectus Supplement No. 6 cover

Closing price $8.80 per share Closing price on April 28, 2026 as reported on Nasdaq

Consulting term 12 months Consulting Agreement effective April 21, 2026

Consulting effective date April 21, 2026 Effective Date of Consulting Agreement

Form 8-K filing date April 29, 2026 Form 8-K attached to Prospectus Supplement No. 6

Executive Severance Plan adoption August 11, 2025 Date Executive Severance Plan was adopted per filing

Key Terms

Prospectus Supplement, Selling Securityholders, Consulting Agreement, Executive Severance Plan, +1 more

5 terms

Prospectus Supplement regulatory

"This prospectus supplement no. 6 (this “Prospectus Supplement”) amends"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Selling Securityholders financial

"63,054,549 Shares of Common Stock by the Selling Securityholders"

Selling securityholders are existing owners of a company's stocks or other tradable claims who are offering some or all of their holdings for sale in a public offering or secondary transaction. Investors watch these sellers because large or insider sales can increase the number of shares available, put downward pressure on price, and signal insiders’ views about future prospects—much like many people selling tickets at once can change the market for an event.

Consulting Agreement legal

"the Company entered into a consulting agreement (the “Consulting Agreement”)"

Executive Severance Plan compensation

"pursuant to the Company’s Executive Severance Plan adopted as of August 11, 2025"

emerging growth company regulatory

"We are an “emerging growth company” as that term is defined"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Offering Details

resale/secondary

Offering

Offering Type resale/secondary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 04:08 PM Learn about SEC filing dates

FAQ

What does BridgeBio Oncology Therapeutics (BBOT) register in this Prospectus Supplement?

The company registers 63,054,549 shares of Common Stock for resale by selling securityholders, as stated on the Prospectus Supplement cover dated April 29, 2026. The supplement amends the Prospectus dated September 10, 2025.

Who became CEO of BridgeBio Oncology Therapeutics according to the Form 8-K?

Pedro J. Beltran, Ph.D. succeeded as President and Chief Executive Officer, effective April 20, 2026. This succession is disclosed in the Form 8-K attached to the Prospectus Supplement.

What are the key terms of Dr. Eli Wallace’s consulting arrangement?

Dr. Wallace entered a consulting agreement effective April 21, 2026 for a twelve-month term, with exclusive compensation consisting of the continued vesting of his outstanding equity awards, subject to providing services through each vesting date.

Does the registration indicate who receives the proceeds from resale?

The Prospectus Supplement describes the sale as by the selling securityholders, which indicates proceeds are not for the issuer; the excerpt does not state any use of proceeds for the company.

What severance protections are disclosed for Dr. Wallace?

The filing states Dr. Wallace is entitled to severance benefits applicable to a Tier 1 officer under the Executive Severance Plan adopted August 11, 2025, as set forth in a Separation Agreement and Release dated April 27, 2026.

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-289940

Prospectus Supplement No. 6

(To Prospectus dated September 10, 2025)

BridgeBio Oncology Therapeutics, Inc.

63,054,549 Shares of Common Stock by the Selling Securityholders

This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 10, 2025 (as may be supplemented or amended from time to time, the “Prospectus”), which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-289940). This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in the attached Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “Securities and Exchange Commission”) on April 29, 2026 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this Prospectus Supplement.

This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.

Our common stock, par value $0.0001 per share (“Common Stock”) is listed on Nasdaq Global Market (“Nasdaq”) under the symbol “BBOT”. On April 28, 2026, the closing price of our Common Stock as reported on Nasdaq was $8.80 per share.

We are an “emerging growth company” as that term is defined under the federal securities laws and, as such, are subject to certain reduced public company reporting requirements.

Investing in our securities involves risks that are described in the “Risk Factors” section beginning on page 10 of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is April 29, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

BridgeBio Oncology Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41955		39-3690783
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

256 E. Grand Avenue, Suite 104

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 405-4770

(Telephone number, including area code, of agent for service)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		BBOT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported in a Current Report on Form 8-K filed by BridgeBio Oncology Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission on April 23, 2026, Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

On April 27, 2026, the Company entered into a consulting agreement (the “Consulting Agreement”) with Dr. Wallace, pursuant to which Dr. Wallace will provide the Company with advisory services regarding the Company’s research and development programs, effective retroactively as of April 21, 2026 (the “Effective Date”) through the date twelve (12) months thereafter (the “Consulting Term”), unless terminated earlier pursuant to the terms of the Consulting Agreement. Dr. Wallace’s exclusive compensation under the Consulting Agreement will be the continued vesting of the outstanding equity awards that he held as of the Effective Date pursuant to the applicable equity incentive plans of the Company, subject to Dr. Wallace providing services to the Company through each applicable vesting date, in accordance with the applicable equity incentive plans and the applicable award agreements. Dr. Wallace’s outstanding stock option grants may also, to the extent vested and exercisable as of the date of termination of the Consulting Agreement, be exercised until the earlier of (i) the date two (2) years after the date of termination of Dr. Wallace’s continued services to the Company as an employee or consultant and (ii) the original expiration date of the applicable stock option grant. Additionally, pursuant to the Company’s Executive Severance Plan adopted as of August 11, 2025 and a Separation Agreement and Release entered into on April 27, 2026, Dr. Wallace is entitled to receive the severance benefits applicable to a Tier 1 officer in connection with a termination by the Company other than for “cause.”

The foregoing summary is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026, and the Executive Severance Plan, which is filed as Exhibit 10.23 to the Company’s Current Report on Form 8-K filed on August 12, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Date: April 29, 2026				By:		/s/ Pedro Beltran
						Name: Pedro Beltran
						Title: President and Chief Executive Officer